While investors chase the usual market darlings, a few underappreciated businesses are quietly gaining traction by generating actual revenue growth, expanding margins, and setting themselves up for long-term success through promising pipelines. As the market seeks profitable innovation in healthcare and biotech, Ardelyx (ARDX) and TScan Therapeutics (TCRX) could be among 2025's most underrated and possibly rewarding stocks.
